Illumina’s Damon Hostin argued that clinical sequencing is moving toward preemptive medicine, but market access and insurance coverage hurdles remain a gating factor. In remarks focused on clinical solutions, Hostin said the field has gained meaningful entry points in specific applications that are already demonstrating value for broader adoption, even as payer policies continue to determine how quickly patients get access.